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Fanconi anemia (FA) is a cancer susceptibility syndromechar-
acterized by sensitivity to DNA-damaging agents. The FA pro-
teins (FANCs) are implicated in DNA repair, although the pre-
cise mechanisms by which FANCs process DNA lesions are not
fully understood. An epistatic relationship between the FA
pathway and translesion synthesis (TLS, a post-replicationDNA
repair mechanism) has been suggested, but the basis for cross-
talk between theFAandTLSpathways is poorly understood.We
show here that ectopic overexpression of the E3 ubiquitin ligase
Rad18 (a central regulator of TLS) induces DNA damage-inde-
pendent mono-ubiquitination of proliferating cell nuclear anti-
gen (PCNA) (a known Rad18 substrate) and FANCD2. Con-
versely, DNA damage-induced mono-ubiquitination of both
PCNA and FANCD2 is attenuated in Rad18-deficient cells,
demonstrating that Rad18 contributes to activation of the FA
pathway. WT Rad18 but not an E3 ubiquitin ligase-deficient
Rad18 C28Fmutant fully complements both PCNA ubiquitina-
tion and FANCD2 activation in Rad18-depleted cells. Rad18-
inducedmono-ubiquitination of FANCD2 is not observed in FA
core complex-deficient cells, demonstrating that Rad18 E3
ligase activity alone is insufficient for FANCD2 ubiquitylation.
Instead, Rad18promotes FA core complex-dependent FANCD2
ubiquitination in a manner that is secondary to PCNA mono-
ubiquitination. Taken together, these results demonstrate a
novel Rad18-dependent mechanism that couples activation of
the FA pathway with TLS.
Genomes are continuously exposed to endogenous and
exogenous DNA-damaging agents, and appropriate coordina-
tion of DNA replication and repair mechanisms is necessary to
prevent genetic instability and cancer (1, 2). Cells have evolved
various systems to sense and repair different types of damaged
DNA throughout the cell cycle.
During S-phase, DNA lesions that escape repair may persist
and cause stalling and collapse of DNA replication forks, a
potential cause of DNA double strand breaks. Translesion
synthesis (TLS)3 is a DNA damage tolerance mechanism that
allows cells to avoid detrimental consequences of persistent
replication stalling (3). TLS involves a “polymerase switch” that
replaces replicative DNA polymerases with specialized TLS
DNApolymerases at stalled replication forks (3–5). Inmamma-
lian cells, the fourmain Y-family TLS polymerases are DNApol
, pol , pol , and REV1 (6). Collectively, the Y-family TLS
polymerases facilitate replicative bypass of various helix-dis-
torting lesions such as bulky adducts, allowing continued fork
progression in cells with DNA damage. However, because of
the relatively low fidelity and processivity of TLS DNA poly-
merases, the ensuing lesion bypass is often error-prone and
preserves replication forks at the cost of mutagenesis (3).
The polymerase switching process is dependent on an E3
ubiquitin ligase termed “Rad18.” In response to replication fork
stalling, Rad18mono-ubiquitinates PCNA at Lys-164 (4, 5). All
Y-family TLS polymerases have specialized ubiquitin-binding
motifs (designated “UBM” and “UBZ” domains) that mediate
their associations with mono-ubiquitinated PCNA (7). Rad18
also contributes to TLS via its direct associations with pol 
which help guide the TLS polymerase to stalled replication
forks (8).Of the fourY-familyTLSpolymerases, pol is the first
to be recruited to most DNA lesions, in part because of Rad18-
mediated chaperone activity. We and others have previously
shown that Rad18 and TLS polymerases are important for
recovery from replication arrest and timely attenuation of
S-phase checkpoint signaling in genotoxin-treated cells (9–11).
Similar to TLS, the Fanconi anemia (FA) DNA repair path-
way is implicated in processing and repairing DNA damage
acquired during S-phase (12, 13). FA is a rare chromosome
instability syndrome associated with increased cancer suscep-
tibility. Gross chromosomal rearrangements following expo-
sure to DNA cross-linking agents, such as mitomycin C
(MMC), diepoxybutane, and cisplatin, is a well known charac-
teristic of cells derived fromFApatients. At least 13 FA comple-
mentation groups (A–C, D1, D2, E–G, I, J, and L–N) have been
identified. The FA proteins (FANCs) encoded by the various
complementation groups are thought to function in a common
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biochemical pathway of DNA repair. The FA core complex
includes protein products of genes belonging to at least eight
FA complementation groups (A–C, E–G, L, andM) and acts as
an E3 ligase to mono-ubiquitinate FANCD2 and FANCI in
response to DNA damage and replication stress during S-
phase. Themono-ubiquitinated FANCD2-I complex, the puta-
tive effector of the FA pathway, is then recruited to chromatin,
and it is thought to direct DNA repair (13).
The FA pathway has been implicated in nuclear excision
repair, homologous recombination, non-homologous end join-
ing, and TLS. A potential link between the FA and TLS path-
ways was suggested based on the hypomutability of FA patient
cell lines after acquisition of psoralen photo-induced lesions
(14, 15), indicating that the FA pathway facilitates an error-
prone repair process. Moreover, Niedzwiedz et al. (16)
demonstrated that DT40 cells deficient in REV1 and REV3 dis-
play cross-linker sensitivity phenotypes that are epistatic to
FANCC. Also, pol  is necessary for FANCD2-FANCI-medi-
ated ICL repair in cell-free Xenopus extracts (17). The finding
that a common de-ubiquitinating enzyme (USP1) regulates the
mono-ubiquitination of both PCNA and FANCD2 (18, 19)
and that Rad6 (an E2 ligase for Rad18 in TLS) status affects
FANCD2 mono-ubiquitination (20) also suggest that the coor-
dination of the FA pathway andTLSmight be important for the
DNA damage response. REV1 focus formation is partially
dependent on the FA core complex in human cells, and FA
patient-derived core complexmutants show reducedmutagen-
esis (14, 15, 21). Interestingly, however, FANCD2-deficient
cells are hypermutable compared with wild type cells (in the
absence or presence of UVC damage) (21), suggesting that the
FA pathway might be forked, with the FANCD2-I ubiquitina-
tion branch responsible for homologous recombination control
and the core complex-dependent branch controlling TLS via
REV1 (22).
Thus, although there is considerable evidence that the FA
and TLS pathways are linked, the molecular mechanisms that
coordinate the FA and TLS pathways are incompletely under-
stood. Furthermore, it is not known whether the FANCs are
necessarily regulated distally or proximally to the TLS pathway
or whether bidirectional communication takes place between
FANCs and TLS proteins. Because a common de-ubiquitinat-
ing enzyme (USP1) negatively regulates both the TLS and FA
pathways (via de-ubiquitination of PCNA and FANCD2,
respectively), we considered the possibility that Rad18might be
responsible for coordinate activation of the two repair path-
ways. Our results described here indicate that FANCD2mono-
ubiquitination is Rad18-dependent. However, we do not find
evidence that FANCD2 is a direct substrate of Rad18. Instead,
our results indicate that the FA pathway is activated in a man-
ner that is coupled to PCNA ubiquitination and TLS polymer-
ase recruitment.
EXPERIMENTAL PROCEDURES
Cell Culture—H1299 cells, HCT116 WT RAD18/, and
RAD18/ cells were obtained from Dr. Tadahiro Shiomi,
Kumamoto University, Japan (23). CRL1162 cells derived from
pol -deficient XPV patients and CRL1162  XPV cells stably
expressing reconstituted WT POLH cDNA were cultured in
Dulbecco’s modified Eagle’s medium supplemented with 10%
fetal bovine serum, streptomycin sulfate (100 g/ml), and pen-
icillin (100 units/ml). FANCD2-deficient PD20 cells, FANCA-
deficient GM6914, and isogenic cell lines stably expressing
reconstituted wild type FANCs (obtained from Dr. Alan
D’Andrea, Dana Farber Cancer Institute) were cultured in Dul-
becco’s modified Eagle’s medium (Invitrogen) supplemented
with 15% fetal bovine serum, streptomycin sulfate (100 g/ml),
and penicillin (100 units/ml). Sf9 insect cells (derived from
Spodoptera frugiperda ovarian cells) were cultured in Sf-900TM
III SFM (Invitrogen).
RNA Interference (RNAi)—The following siRNA oligonucleo-
tides (Dharmacon, Lafayette, CO) were used for the experiments
in this study: pol , 5-GCA GAA AGG CAG AAA GUU A-3;
Rad18, On-Target plus SMART POOL (L-004591, Dharmacon);
UBE2T, 5-GAA GAG AGAGCT GCA CAT GTT-3; and non-
targeting control siRNA oligonucleotides (D-001210-01,
Dharmacon). Lipofectamine 2000 (Invitrogen) was used for
transfection of all the siRNA oligonucleotides, following the
manufacturer’s protocol. All tubes, tips, and solutions used for
RNA interference experiments were certified RNase-free.
SDS-PAGE and Immunoblotting—Total cell lysates were
prepared in lysis buffer containing 50 mM Hepes, pH 7.4, 0.1%
Triton X-100, 150 mM NaCl, 1 mM EDTA, 50 mM NaF, 80 mM
-glycerophosphate, supplementedwith protease inhibitor and
phos-stop (Roche Applied Science). In some experiments, cells
were fractionated to generate soluble fractions and whole
nuclei, exactly as described by Izumi et al. (24). In brief, mono-
layers of cells were washed two times with ice-cold phosphate-
buffered saline (PBS) and scraped into 500 l of ice-cold
cytoskeleton buffer (10 mM PIPES, pH 6.8), 100 mM NaCl, 300
mM sucrose, 3mMMgCl2, 1mM EGTA, 1mM dithiothreitol, 0.1
mM ATP, 1 mM Na3VO4, 10 mM NaF, and 0.1% Triton X-100)
freshly supplemented with protease inhibitor and phos-stop
(RocheApplied Science). Cytoskeleton lysates were transferred
to microcentrifuge tubes and incubated on ice for 5 min. The
cell lysates were centrifuged at 1000  g for 2 min. The super-
natants were removed and further clarified by centrifugation at
10,000 g for 10min to obtain Triton X-100-soluble fractions.
The Triton X-100-extracted insoluble nuclear fractions were
washed once with 1 ml of cytoskeleton buffer and then resus-
pended in a minimal volume of cytoskeleton buffer. Soluble or
nuclear protein samples were separated by SDS-PAGE, trans-
ferred to nitrocellulose, and analyzed by immunoblotting with
appropriate antibodies. Bound antibodies were visualized using
ECL. Films were scanned and analyzed by densitometry using
ImageJ software to compare relative expression levels of various
proteins.
FluorescenceMicroscopy—H1299 or HCT116 cells exponen-
tially growing in two-well chamber slides were infected with
Ad-Rad18 for 48 h. The resulting slides were further treated
with BPDE or UV genotoxins or left untreated. Cells were
washed with PBS and incubated with cold CSK buffer on ice for
10 min. Cell nuclei were fixed with 4% paraformaldehyde in
CSK for 15 min at room temperature and washed with PBS.
After washing with PBS, cells were permeabilized with 0.5%
TritonX-100 for 5min. Slides werewashed againwith PBS, and
cells were incubated overnight at 4 °C with anti-FANCD2 anti-
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bodies (sc-20022,mouse) in 3% bovine serum albumin (BSA) in
PBS containing 0.1% Triton X-100 (PBST). The slides were
washed three times with 1% BSA/PBST and incubated with
anti-mouse IgG-FITC antibodies or anti-mouse IgG-Cy3 anti-
bodies (C2181, Sigma) for 2 h at room temperature. Afterwash-
ing with PBST, the slides were DAPI-stained, mounted with
VECTASHIELD Mounting Medium (Vector Laboratories),
imaged, and analyzed with a DeltaVision image restoration
microscopy system (dv1301421; Applied Precision).
Genotoxin Treatments—BPDE (NCI Carcinogen Repository,
National Institutes of Health) was dissolved in anhydrous
Me2SO and added directly to the growth medium as a 1000
stock to give final concentrations of 100, 200, 300, or 500 nM.
MMC was dissolved in 50% ethanol added directly to the
growth medium as a 1000 stock to give a final concentration
of 300 nM. For UVC treatment, the growth medium was
removed from the cells and replaced with PBS. The plates were
transferred to a UV cross-linker (Stratagene) and then irradi-
ated. The UVC dose delivered to the cells was confirmed with a
UV radiometer (UVP, Inc.). The cells were then re-fed with
complete growth medium and returned to the incubator.
Adenovirus Construction and Infection—All adenovirus vec-
tors were constructed and purified as described previously (9,
10). Briefly, various cDNAs were subcloned into pAC-CMV.
The resulting shuttle vectors were co-transfected into 293T
cells with the pJM17 plasmid to generate recombinant adeno-
virus, and adenovirus particles were purified from 293T cell
lysates by polyethylene glycol precipitation, CsCl gradient cen-
trifugation, and gel filtration column chromatography. Adeno-
virus infections were performed by direct addition of purified
virus to the tissue culture medium. Expression of adenovirus-
encoded proteins was confirmed by immunoblotting. Cells
were routinely infected with 5  109 plaque-forming units/ml
of adenovirus.
In Vitro Ubiquitination Assays—Recombinant full-length
wild type FANCD2 was purified using recombinant baculovi-
rus-infected Sf9 insect cells as described by Park et al. (25).
Briefly, Sf9 cells were infected with baculovirus encoding zz-
tagged FANCD2 (obtained from Dr. Jeffery Parvin, Ohio State
University) for 4 days. The infected cells were harvested and
washed in chilled phosphate-buffered saline. Cells were lysed in
15 ml of buffer B (20 mM Hepes, pH 7.9, 20% glycerol, 200 mM
KCl, 0.5 mM EDTA, 0.5% Nonidet P-40, 0.5 mM dithiothreitol,
supplemented with Complete-mini (Roche Applied Science)).
The pre-equilibrated 250l of IgG-Sepharose (AmershamBio-
sciences) was added into the protein lysate and incubated with
mixing at 4 °C for 16 h. The resulting protein-IgG-Sepharose
complexes were washed twice with buffer B and twice with
buffer C (20 mM Hepes, pH 7.9, 20% glycerol, 200 mM KCl, 0.5
mM EDTA, 0.1% Nonidet P-40, 0.5 mM dithiothreitol), four
times with TEV cleavage buffer (10 mM Tris-HCl, pH 8.0, 150
mM NaCl, 0.1% Nonidet P-40, 0.5 mM EDTA, 0.5 mM dithio-
threitol), and then resuspended in 300 l of TEV cleavage
buffer plus 18 g of TEV enzyme (Invitrogen). Beads contain-
ing the bound fusion protein were incubated with the TEV pro-
tease at 4 °C for 16 h. The supernatant containing FANCD2
protein was resolved by SDS-PAGE, stained with Coomassie
Blue to estimate protein concentration, and used for in vitro
ubiquitination assay. As an alternative source of FANCD2 pro-
tein for in vitro ubiquitination assay, FANCD2 was immuno-
precipitated from PD20  FLAG-FANCD2 reconstituted cells.
Cells were lysed and fractionated using CSK buffer as described
above, and the soluble fraction of the cell lysates was used for
immunoprecipitation to enrich nonubiquitinated FANCD2
protein. Anti-FLAG M2 Affinity gel (Sigma) was incubated
with the soluble cell lysate at 4 °C for 16 h, washed five times
with wash buffer (20 mM Tris, pH 7.5, 0.1 M NaCl, 0.1 mM
EDTA, 0.05% Tween 20), and eluted with 5 volumes of 0.2
mg/ml FLAG peptide (Sigma). In vitro ubiquitination assays
were performed as described by Tateishi and co-workers (8)
using recombinant PCNA recombinant protein as a positive
control for the Rad6-Rad18-mediated ubiquitination. Briefly,
purified recombinant FANCD2 or PCNA proteins were incu-
bated for 1 h at 25 °C with RAD6B-RAD18 complexes (26) in a
buffer containing 50 mM Hepes, pH 7.6, 0.05 mM DTT, 1 mM
MgCl2, 1 mM ATP, and an ATP-regenerating system together
with either 5 mM ubiquitin (Boston Biochem) or GST-ubiq-
uitin. The reaction mixtures were analyzed by SDS-PAGE and
immunoblotting with anti-FANCD2 or anti-PCNA antibodies.
Reproducibility—All data shown are representative of exper-
iments that were performed at least three times on separate
occasions with similar results.
RESULTS
FA Pathway Activation in Response to BPDE-induced Bulky
DNAAdducts—Wehave previously shown a key role for Rad18
and TLS polymerases in mediating attenuation of S-phase
checkpoint signaling elicited by BPDE lesions (9, 10). Because
the FA pathway is implicated in TLS (14–16, 21, 22), it was of
interest to test the possible role of FANCD2 in the DNA dam-
age response to BPDE (9, 10). H1299 cells were treatedwith 100
nM BPDE for 2 h to induce DNA damage, and the cell lysates
were analyzed for FANCD2 and other DNA replication and
S-phase checkpoint proteins. As expected, BPDE inducedChk1
phosphorylation at Ser-317 and decreased chromatin loading
of Cdc45 (Fig. 1A), demonstrating activation of S-phase check-
point signaling. BPDE also induced mono-ubiquitination of
PCNA and FANCD2 under these experimental conditions (Fig.
1A, left panels). In response to genotoxins or during S-phase,
FANCD2 redistributes to distinct nuclear foci likely corre-
sponding to DNA replication and repair factories (28, 29). We
tested the effect of BPDE on FANCD2 subcellular distribution
by immunofluorescence microscopy. As shown in Fig. 1B,
BPDE treatment increased the number of FANCD2nuclear foci
by 5.5-fold (p 0.00015). FANCD2 foci were partially co-local-
izedwith pol  (Fig. 1C), the TLS polymerase involved in bypass
of BPDE-induced DNA lesions (9, 10). Therefore, BPDE in-
duces concomitant activation of checkpoint signaling, Rad18-
dependent TLS, and FANCD2 ubiquitination.
TLS deficiency delays the recovery from S-phase check-
points,most likely due to impaired processing and resolution of
stalled fork structures when post-replication repair is compro-
mised (9, 10). Given the suspected relationship between the FA
pathway and TLS, it was of interest to determine the potential
requirement for FANCD2 in mediating recovery from BPDE-
induced S-phase arrest. Therefore, we measured rates of DNA
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synthesis at different times after BPDE treatment in control and
FANCD2-depleted H1299 cells. As shown in Fig. 1D, resump-
tion of DNA synthesis following BPDE treatment was delayed
in FANCD2-depleted H1299 cells relative to controls. We also
compared rates of DNA synthesis after BPDE treatment in
FANCD2() PD20 FA patient cells and an isogenic FLAG-
FANCD2-complemented cell line (designated FANCD2()).
Qualitatively similar to the results of experiments with
FANCD2-depleted H1299 cells, resumption of DNA synthesis
following BPDE-induced S-phase arrest was delayed in the
FIGURE 1. Role of FANCD2 in the cellular response to BPDE. A, H1299 cells were treated with 100 nM BPDE for 2 h or left untreated for controls. Soluble (sol)
and chromatin (chr) extracts from the resulting cells were analyzed by SDS-PAGE and immunoblotting with anti-FANCD2, MCM7, Cdc45, phospho-Chk1
(Ser-317), PCNA, and cyclin A antibodies (left panel). The chromatin-bound (mono-ubiquitinated) FANCD2 is designated “FANCD2-Ub.” B, in parallel with the
experiment described in A above, H1299 cells growing in chamber slides were treated with 100 nM BPDE for 4 h or left untreated. Cells were washed with CSK
buffer to remove soluble proteins, fixed with 4% paraformaldehyde, and stained with anti-FANCD2 antibodies. FANCD2 nuclear foci were visualized by
Deltavision immunofluorescence microscopy. FANCD2 foci in 10 representative nuclei from control (BPDE) and BPDE-treated (BPDE) cells were enumerated.
Data points represent the mean number of foci for 10 representative cells, with error bars representing the range. *, p  0.00015 compared with control cells
that did not receive BPDE. C, GFP-pol -expressing H1299 cells growing in chamber slides were treated with 100 nM BPDE for 4 h or left untreated. Cells were
fixed and stained with anti-FANCD2 antibodies as described under “Experimental Procedures.” FANCD2 and GFP nuclear foci were visualized by Deltavision
immunofluorescence microscopy. D, effect of FANCD2 deficiency on DNA synthesis in genotoxin-treated cells. H1299 cells were transfected with siRNA against
FANCD2 (or with nontargeting control siRNA oligonucleotides). The resulting cells were treated with 60 nM BPDE, and at various times, the rates of DNA
synthesis were determined by measuring the rates of thymidine incorporation. E, DNA synthesis assays similar to those performed in D above were conducted
in FANCD2() and FANCD2() cells at the indicated times after treatment with 50 nM BPDE and 250 M cisplatin. F, exponentially growing FANCD2() and
FANCD2() cells were treated with different doses of BPDE as indicated. 24 h later, cells were trypsinized and re-plated in replicate on 10-cm plates at a density
of 1000 cells/plate. The growth medium on the re-plated cells was replenished every 3 days. After 10 days, colonies of 50 cells were stained with crystal violet
and then counted.
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FANCD2() cell line relative to FANCD2() cells (Fig. 1E). As
expected, recovery from S-phase arrest following treatment
with the intra-strand cross-linking agent (cis-platinum, cispla-
tin) was also compromised in FANCD2() cells relative to
FANCD2() controls (Fig. 1E). Furthermore, consistent with
a role for FANCD2 in tolerance of BPDE-induced DNA dam-
age, FANCD2() cells showedmodest sensitivity to BPDE in
cell survival assays (Fig. 1F). Other workers have also
reported mild UV sensitivity of FA cell lines (30), further
indicating a role for FANCs in tolerance of bulky DNA lesions.
Taken together, our results show that the FA pathway partici-
pates in cellular responses to bulky DNA adducts such as
BPDE-induced lesions.
Rad18 Promotes Efficient FANCD2 Mono-ubiquitination—
Because FANCD2 associated with chromatin in response to
BPDE (Fig. 1), and because FANCD2 deficiency recapitulated
the S-phase recovery and survival defects of TLS-deficient cells
(9, 10), we hypothesized that TLS and FANC proteins function
in a common pathway that confers tolerance of bulky adducts.
Therefore, we first tested the possibility that FANCD2ubiquiti-
nation is downstream of Rad18.
Wehavepreviously shown thatBPDE-inducedPCNAmono-
ubiquitination is Rad18-dependent and that overexpressed
Rad18 induces DNA damage-independent PCNA ubiquitina-
tion (10). As shown in Fig. 2A, Rad18 overexpression in H1299
cells also induced a distinct FANCD2 electrophoretic mobility
shift (the hallmark of FANCD2 mono-ubiquitination), even in
the absence of DNA damage. Therefore, Rad18 is a potential
upstream regulator of the FA pathway.
Endogenous RAD18 Facilitates Mono-ubiquitination of
FANCD2—To test whether endogenous Rad18 contributes to
FA pathway activation, we determined the effect of depleting
endogenous Rad18 on genotoxin-inducible association of
mono-ubiquitinated FANCD2 with chromatin.
As expected, genotoxin treatments (BPDEorMMC) induced
robust mono-ubiquitination of chromatin-associated PCNA
and increased the chromatin association of FANCD2 in control
(siCon) transfected cells (Fig. 2B, 2nd and 3rd lanes). Interest-
ingly, both PCNAmono-ubiquitination and FANCD2 chroma-
tin binding were reduced in Rad18-depleted H1299 cells (Fig.
2B, 6th and 7th lanes). The protein levels of soluble (nonubiq-
uitinated) FANCD2 were unaffected by Rad18 status.
To complement our Rad18 siRNA experiments, we exam-
ined basal and genotoxin-induced levels of FANCD2 ubiquiti-
nation in RAD18/ and RAD18/ HCT 116 cells (23). Basal
levels of chromatin-associated (mono-ubiquitinated) FANCD2
were 5-fold lower in RAD18/ cells relative to RAD18/
HCT116 cells (Fig. 2C). Levels of soluble FANCD2proteinwere
similar between RAD18/ and RAD18/ cell lines. It was
formally possible that the impaired chromatin association of
FANCD2 in RAD18/ cells was due to RAD18-independent
differences between the two cell lines. Potentially, genetic
changes resulting from long term cell culture of the RAD18/
cells might have resulted in disruption of the FA pathway.
Therefore, we reconstituted Rad18 expression in RAD18/
cells using transient adenovirus-mediated gene delivery. The
expression levels of Rad18 expression in the reconstituted cells
were similar to Rad18 levels in parental RAD18/ HCT116
FIGURE 2. Rad18 promotes efficient FANCD2 ubiquitylation. A, exponen-
tially growing H1299 cells were infected with adenovirus encoding HA-Rad18
(or with empty vector control “AdCon” virus). 48 h post-infection, total cell
lysates were analyzed by SDS-PAGE and immunoblotting for FANCD2. B, con-
trol (siCon) and Rad18-depleted (siRad18) cells were treated with 300 nM MMC
or 300 nM BPDE for 6 h. Some cultures were additionally infected with AdHA-
Rad18 adenovirus for 48 h prior to genotoxin treatment, as indicated. Chro-
matin (chr) and soluble (sol) fractions from the resulting cells were analyzed
by SDS-PAGE and immunoblotting with antibodies against FANCD2, Rad18,
and PCNA. C, soluble and chromatin fractions from exponentially growing
HCT116 RAD18/ and RAD18/ cells were analyzed by SDS-PAGE and
immunoblotting with antibodies against FANCD2 and Rad18. D, HCT116
RAD18/ cells were infected with adenovirus encoding FLAG-Rad18 for 48 h.
The resulting cells were treated with 10 J/m2 UVC (or were left untreated for
controls (Con)). 2 h after UV treatment, cells were lysed, and whole cell
extracts were analyzed by SDS-PAGE and immunoblotting with antibodies
against FANCD2 and Rad18. E, RAD18/ HCT116 cells growing in chamber
slides were infected with adenovirus encoding FLAG-Rad18 or with an
“empty” vector control adenovirus (AdCon) for 48 h. The resulting slides were
washed with CSK, and FANCD2 nuclear foci were visualized as described for
Fig. 1B. FANCD2 foci in 50 representative nuclei from AdCon- and AdRad18-
infected cells were enumerated. Data points represent the mean number of
foci for 50 representative cells, with error bars representing the range. *, p 
0.0001 compared with control cells that were infected with control adenovi-
rus. Note that we typically observe 10-fold fewer basal and genotoxin-in-
ducible FANCD2 nuclear foci in HCT116 cells when compared with H1299
cells (for example compare Figs. 1B, 2E, and 4C).
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cells (Fig. 2D). As expected, levels of mono-ubiquitinated
FANCD2 (upper bands of FANCD2 doublet designated
“FANCD2-long”) were decreased in RAD18/ cells relative to
wild type cells (Fig. 2D, 1st and 3rd lanes). However, reconsti-
tution of RAD18 in RAD18-null cells restored mono-ubiquiti-
nation of FANCD2, resulting in a distinct band shift (Fig. 2D,
2nd lane). UV treatment did not induce FANCD2 mono-ubiq-
uitination as efficiently inRAD18/ cellswhen comparedwith
RAD18/ cells (Fig. 2D, 4th and 6th lanes). However, in
Rad18-complementedRAD18/ cells, UV radiation induced a
level of FANCD2 mono-ubiquitination that was comparable
with that observed in wild type cells (Fig. 2D, 5th lane).
FANCD2 mono-ubiquitination is necessary for its redistri-
bution to nuclear foci (28, 29). We performed immunofluores-
cence microscopy to monitor the effect of Rad18 complemen-
tation on the subcellular localization of FANCD2 in RAD18/
cells. As shown in Fig. 2E, ectopically expressed FLAG-Rad18
induced a 4-fold increase in the number of FANCD2 nuclear
foci (p  0.0001), further consistent with a role for Rad18 in
facilitating efficient FANCD2 mono-ubiquitination. Taken
together, our results demonstrate that Rad18 promotes
FANCD2 mono-ubiquitination and formation of FANCD2
nuclear foci, consistent with a role for Rad18 in regulating the
FA pathway.
Purified RAD6-RAD18Complex Is Insufficient toMono-ubiq-
uitinate FANCD2 in Vitro—The results of Fig. 2 indicated that
Rad18 contributes to basal and genotoxin-induced FANCD2
ubiquitination in human cells. In co-immunoprecipitation
experiments, we noticed both basal and genotoxin-inducible
association of RAD18 and FANCD2 (data not shown). There-
fore, we performed in vitro ubiquitination assays to test the
possibility that FANCD2 is a direct target of RAD18 E3 ligase
activity. Recombinant human FANCD2 (expressed and puri-
fied from insect cells) and immunoprecipitated FLAG-
FANCD2 from human PD20 cells were both tested as possible
substrates of Rad18-Rad6. Recombinant PCNA was used as a
positive control substrate for ubiquitination by Rad18 (8, 26).
As expected, the recombinant Rad6-Rad18 complex mono-
ubiquitinated PCNA effectively, as shown by the appearance of
an electrophoretically shifted form of PCNA (Fig. 3A). Using
GST-tagged ubiquitin, we also verified that the band shift truly
resulted from mono-ubiquitination of PCNA by the Rad6-
Rad18 complexes (Fig. 3A, 4th lane). However, in parallel in
vitro ubiquitination assays containing recombinant FANCD2
as a candidate substrate, we did not detect the mono-ubiquiti-
nated species of FANCD2 (Fig. 3A, 2nd and 3rd lanes). Neither
insect cell-derived FANCD2 (Fig. 3A) nor immunopurified
FLAG-FANCD2 prepared from human PD20 fibroblasts were
in vitro substrates for Rad18-Rad6 (Fig. 3B, 3rd and 6th lanes).
Although these results do not exclude the possibility that
FANCD2 is a physiological substrate of Rad18 within intact
cells, they indicate that active purified Rad6-Rad18 is insuffi-
cient to ubiquitinate FANCD2. We infer that either additional
proteins are necessary to facilitate direct ubiquitination of
FANCD2 by Rad18 or that Rad18 activates the FA pathway
indirectly. Experiments described below suggest that Rad18-
mediated FA pathway activation occurs indirectly and is sec-
ondary to other TLS events.
Role of RAD18-mediated PCNA Mono-ubiquitination in FA
Pathway Activation—We hypothesized that Rad18-induced
mono-ubiquitination of FANCD2 might occur indirectly, sec-
ondarily to PCNA mono-ubiquitination and recruitment of
TLS polymerases. The SAP (SAF-A/B, Acinus, and PIAS)
domain of RAD18 (residues 248–282) is necessary for the effi-
cientmono-ubiquitination of PCNAandpol recruitment (26)
but is dispensable for other Rad18 functions (31). Therefore, to
investigate a correlation between PCNA ubiquitination and FA
pathway activation, we tested the effect of a SAP domainmuta-
tion (	SAP) on Rad18-induced FANCD2 ubiquitination.
As shown in Fig. 4A, ectopic expression of the WT form of
RAD18 induced DNA damage-independent mono-ubiquiti-
nation of PCNA and FANCD2. As expected, overexpression
of Rad18 	SAP did not promote PCNA mono-ubiquitination
and also failed to induce FANCD2mono-ubiquitination. These
data suggested that mono-ubiquitination of PCNA might be a
prerequisite for RAD18-induced mono-ubiquitination of
FANCD2.
To further test the role of Rad18E3ubiquitin ligase activity in
promoting FANCD2 mono-ubiquitination, we used a RING
domain pointmutant of Rad18 (designated “Rad18C28F”). The
Rad18 C28Fmutant lacks ubiquitin ligase activity, yet supports
DNA repair via homologous recombination repair (31). In the
experiment shown in Fig. 4B, partial depletion of Rad18 using
FIGURE 3. Recombinant Rad18-Rad6 complex ubiquitinates PCNA but
not FANCD2 in vitro. A, Rad18-Rad6 complexes were incubated with recom-
binant PCNA or recombinant baculovirus-encoded FANCD2 purified from Sf9
cells as described under “Experimental Procedures.” Reaction products were
analyzed by SDS-PAGE and immunoblotting with antibodies against PCNA or
FANCD2. B, Rad18-Rad6 complexes were incubated with immunoprecipi-
tated FANCD2 complexes from FLAG-FANCD2-complemented PD20 cells.
Immobilized FLAG-FANCD2 bound to the anti-FLAG affinity matrix (“beads”)
and FLAG-FANCD2 eluted using FLAG peptides (“eluate”) were both tested as
potential Rad18 substrates as indicated.
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siRNA reduced chromatin association of FANCD2 by 55%.
The ectopic expression of siRNA-resistantWTRad18 fully cor-
rected the reduced basal and genotoxin-inducible chromatin
association of FANCD2. However, when expressed at similar
levels to WT Rad18, the Rad18 C28F mutant failed to induce
PCNA mono-ubiquitination and did not correct the defective
FANCD2 chromatin association of Rad18-depleted cells (Fig.
4B).We conclude that Rad18 E3 ubiquitin ligase activity is nec-
essary to promote efficient FANCD2ubiquitination.Moreover,
these data show that the Rad18-mediated FA pathway activa-
tion is separable from the E3 ligase-independent role of Rad18
in DNA repair via homologous recombination (31).
We reasoned that if RAD18-induced FANCD2 mono-ubiq-
uitination occurs secondarily to PCNA mono-ubiquitination,
expression of a PCNA-ubiquitin fusion protein that mimics
native mono-ubiquitinated PCNA (7) may confer FA pathway
activation independently of Rad18. We generated an adenovi-
rus encoding HA-tagged PCNA-ubiquitin fusion protein (des-
ignated “PCNA-Ub*”). To test whether the PCNA-Ub* protein
recruits TLS polymerases independently of genotoxin treat-
FIGURE 4. Mono-ubiquitinated PCNA and pol  promote efficient FANCD2 mono-ubiquitination. A, H1299 cells were transiently transfected with vectors
encoding FLAG-Rad18 WT or FLAG-Rad18	 SAP or with an empty vector (pcDNA) for control. 48 h later, the resulting cells were analyzed by SDS-PAGE and
immunoblotting with antibodies against FANCD2, PCNA, and FLAG (to detect RAD18). B, H1299 cells were transfected with plasmids encoding Myc-Rad18 (WT)
or Myc-Rad18 (C28F) or with an empty vector (pcDNA) for control. 24 h later the cells were transfected with siRNA directed against the 3UTR of Rad18 or with
a nontargeting control siRNA (siCon). After an additional 24 h, the cells were treated with 600 nM BPDE (or DMSO for controls). 6 h later, cell extracts were
prepared and analyzed by SDS-PAGE and immunoblotting with antibodies against FANCD2, PCNA, and RAD18. C, H1299 cells were infected with adenovirus
vectors encoding GFP-pol  and HA-PCNA-Ub* fusion protein. The subcellular distribution of GFP-pol  or FANCD2 in the resulting cultures was determined by
DeltaVision fluorescence microscopy. Images of representative cells are shown. FANCD2 foci in 10 representative nuclei from AdCon- and AdPCNA-UB*-
infected cells were enumerated. Data points represent the mean number of foci for 10 representative cells, with error bars representing the range. *, p  0.0001
compared with control cells that were infected with control adenovirus (AdCon). D, H1299 cells were infected with AdHA-PCNA-Ub* or a control empty
adenovirus vector (AdCon). After 48 h, chromatin and soluble extracts from the resulting cells were analyzed by SDS-PAGE and immunoblotting with antibodies
against FANCD2, FANCI, pol , and PCNA. E, HCT116 RAD18/ cells were infected with AdHA-PCNA-Ub*. After 48 h, extracts from the resulting cells were
analyzed by SDS-PAGE and immunoblotting using antibodies against FANCD2, pol  and PCNA. F, H1299 cells expressing FLAG-Rad18 were transfected with
siPol or control nontargeting siRNA (siCon). The resulting cells were treated with UVC (10 J/m2). Cell extracts were prepared 2 h after UV treatment and
analyzed by SDS-PAGE and immunoblotting using antibodies against FANCD2, pol , and phospho-Chk1 (Ser-317).
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ment, we co-expressed HA-PCNA-Ub* and GFP-pol  in
H1299 cells and monitored the effect of the PCNA-Ub* fusion
protein on GFP-pol  distribution.
As shown in Fig. 4C, PCNA-Ub* expression redistributed
GFP-pol  to nuclear foci in the absence of DNA damage, ver-
ifying that the PCNA-ubiquitin fusion protein mimics native
mono-ubiquitinated PCNA. In parallel fluorescence micros-
copy experiments, PCNA-Ub* induced a 5.8-fold increase in
the number of basal FANCD2 nuclear foci (p 0.0001). Images
of representative cells containing PCNA-Ub*-induced nuclear
foci are shown in Fig. 4C.
The effect of PCNA-Ub* on the subcellular distribution of
FANCD2 further suggests that PCNA ubiquitination may con-
tribute to activation of the FA pathway. As shown in Fig. 4D,
increased chromatin association of FANCD2 and FANCI in
response to PCNA-Ub* expression was also evident by immu-
noblotting. As expected, chromatin loading of endogenous pol
 was increased in response to PCNA-Ub* (Fig. 4C).
The H1299 cells used for experiments shown in Fig. 4, A–D,
express functional wild type Rad18 protein. To test whether the
expression of PCNA-Ub* can induce mono-ubiquitination of
FANCD2 in the absence of Rad18, we infected RAD18/ cells
withAdHA-PCNA-Ub*. As shown in Fig. 4E, chromatin load-
ing of the TLS polymerase pol  was increased upon PCNA-
Ub* expression (albeit to a lesser degree than in H1299 cells,
probably because of the important role of Rad18 in guiding
pol  to stalled replication forks). Interestingly, chromatin
association of FANCD2 was increased in response to PCNA-
Ub* expression, even in a RAD18/ background (Fig. 4E).
Taken together, our results suggest that Rad18-dependent
mono-ubiquitination of FANCD2occurs secondarily to Rad18-
mediated PCNA modification.
pol  Promotes Efficient FANCD2 Mono-ubiquitination—It
was of interest to determine whether FANCD2 ubiquitination
is coupled directly to PCNA ubiquitination or to more distal
event(s) such as TLS polymerase recruitment. The Y-family
TLS polymerases pol , pol , pol , as well as REV1 are all
thought to associate with ubiquitinated PCNA via specialized
ubiquitin-binding motifs. Potentially, recruitment of any one
(or all) Y-family polymerase may be linked to subsequent acti-
vation of the FA pathway. We chose to focus on pol  as a
candidate mediator of FANCD2 activation for several reasons
as follows.Of theY-familymembers, polhas the highest affin-
ity for PCNA and is likely the first TLS polymerase recruited to
all stalled replication forks (32). Moreover, pol  is a versatile
TLS polymerase, which can cope with many types of lesions.
Indeed, for some lesions (including UV-induced cyclobutane
pyrimidine dimers), pol  performs insertion and extension
steps without the requirement for additional TLS enzymes (3).
To test whether pol  mediates Rad18/PCNA-Ub-in-
duced FANCD2 mono-ubiquitination, we depleted pol  by
siRNA-mediated knockdown in H1299 cells. Interestingly,
depletion of pol  attenuated the genotoxin-inducible associa-
tion of FANCD2 with chromatin (Fig. 4F). As expected from
our previous work (9), UV-inducible Chk1 phosphorylation
was increased (by 2.7-fold) as a result of pol  depletion (Fig.
4F). Therefore, the reduced activation of FANCD2 in pol -de-
pleted cells was not due to a general decrease in DNA damage
signaling. Taken together, these data support our hypothesis
that recruitment of TLS polymerases to DNA replication forks
stalled by bulky lesions is coupled to the activation of the
Fanconi anemia pathway.
Effect of Rad18 Status on the FA Core Complex Proteins—We
considered possible mechanisms by which TLS polymerase
recruitment might be linked to FANCD2 ubiquitination. The
intact FA core complex is necessary formono-ubiquitination of
FANCD2 in vivo, although USP1 de-ubiquitinates FANCD2
both in vivo and in vitro (18, 19, 33–36). Potentially, Rad18-de-
pendent TLS could promote FANCD2 ubiquitination via
increased FA core complex activity, reduced USP1-dependent
de-ubiquitylation, or via both mechanisms. Therefore, we
determined whether FA core complex proteins are differently
regulated in RAD18/ cells compared with RAD18/ cells.
As shown in Fig. 5A, levels of chromatin-bound FANCA
were 2-fold higher in RAD18/ cells relative to RAD18/
cells (although levels of soluble FANCA were similar between
the two cell lines). We have also observed reduced recruitment
of FANCA to chromatin in Rad18-depleted H1299 cells (data
not shown). For the purpose of comparison,we also determined
protein levels of FANCG in the same experiment. As shown in
Fig. 5A, chromatin-associated FANCGwas 1.5-foldmore abun-
dant in RAD18/ cells relative to the RAD18-null line. How-
ever, for reasons that are unclear, expression of soluble FANCG
was also reduced in RAD18/ cells relative to the parental
RAD18/ cell line. Nevertheless, these results are consistent
with a role for Rad18 in regulating recruitment of the FA core
complex to chromatin.
Because PCNA mono-ubiquitination and TLS polymerases
influenced FANCD2mono-ubiquitination, we also determined
the effect of PCNA-Ub* expression on the levels of chromatin-
bound and soluble FANCA. As shown in Fig. 5B, expression of
PCNA-Ub* stimulated accumulation of FANCA on chromatin
but did not modify levels of soluble FANCA. Conversely, in pol
-depleted cells, genotoxin-induced association of FANCA
with chromatin was attenuated (Fig. 5C). Taken together, these
results suggest that efficient FANCD2 mono-ubiquitination is
conferred by Rad18-mediated PCNAmono-ubiquitination and
subsequent recruitment of TLS polymerases, leading to associ-
ation of the FA core complex with chromatin.
FA Core Complex Is Necessary for the Rad18-induced Com-
ponent of FANCD2 Ubiquitination—To test whether the FA
core complex is necessary for Rad18-mediated FANCD2
mono-ubiquitination, FANCA () GM6914 cells and an iso-
genic FANCA () cell line complemented with wild type
FANCA cDNA were infected with Ad-FLAG-RAD18, infected
with AdHA-PCNA-Ub*, or treated with MMC as a positive
control for FA pathway activation. As expected, MMC treat-
ment induced mono-ubiquitinated FANCD2 on chromatin in
FANCA () cells but not in FANCA () cells (Fig. 5D, 3rd and
4th lanes). Overexpression of Rad18 or of PCNA-Ub* increased
accumulation of FANCD2 on chromatin in the FANCA ()
cells by 3-fold (Fig. 5D, 5th and 7th lanes), but these condi-
tions did not affect chromatin binding of FANCD2 in FANCA-
deficient cells (Fig. 5D, 6th and 8th lanes). Therefore, Rad18
expression or mono-ubiquitination of PCNA alone were insuf-
ficient for FANCD2 mono-ubiquitination in FANCA () cells,
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further suggesting that Rad18-mediated FANCD2mono-ubiq-
uitination is indirect and requires the FA-core complex.
UBE2T is the ubiquitin E2 ligase thought to mediate
FANCD2 ubiquitylation. Therefore, we additionally tested
whether UBE2T is necessary for Rad18-mediated mono-ubiq-
uitination of FANCD2. We performed siRNA to deplete
UBE2T expression. In those experiments, ablation of UBE2T
was very toxic to H1299 cells (data not shown) and led to
reduced expression levels of cyclin A and PCNA and reduced
numbers of cells in S-phase (Fig. 5E). However, as shown in Fig.
5E, 7th and 8th lanes, RAD18-mediated FANCD2 mono-ubiq-
uitination was compromised in UBE2T-depleted cells. There-
fore, consistent with the results of Fig. 5D, RAD18-dependent
mono-ubiquitination of FANCD2 likely occurs indirectly via
activation of the FA core complex.
Genotoxin-induced PCNA Mono-ubiquitylation in FA Cells—
The results of Figs. 1–5 indicate that FA pathway activation
occurs distal to Rad18-induced PCNAubiquitylation, at least in
the context of human cells that acquire bulky DNA lesions. In
contrast, recent studies using replication-competent Xenopus
cell-free extracts suggest that when replication forks converge
on ICL, TLS events occur distal to the FA core complex and
FANCD2-FANCI activation (17, 37). Therefore, we tested
whether an intact FA pathway is required for PCNA ubiquity-
lation.We tested the effect of FANCD2 or FANCI depletion on
the integrity of genotoxin-induced PCNA ubiquitylation. As
shown in Fig. 6, we observed slightly reduced PCNA ubiquity-
lation in FANCD2- and FANCI-depletedH1299 cells relative to
controls. However, we have found that FANCD2 deficiency
results in reduced origin firing in many cultured cell lines,
including H1299 (38). Therefore, the attenuated PCNA
ubiquitylation observed following FANCD2/FANCI deple-
tion likely results from reduced numbers of replicons in
these cells. Indeed, DNA damage-inducible phosphorylation
of Chk1 (which, similar to PCNA ubiquitylation, requires
replication fork-dependent generation of replication protein
A-coated ssDNA) was also attenuated in FANCD2- and
FANCI-depleted cells (Fig. 6).We conclude that FANCD2 defi-
ciency does not directly compromise Rad18-mediated PCNA
mono-ubiquitination.
DISCUSSION
Here we have demonstrated that FANCD2 mono-ubiquiti-
nation is regulated by Rad18 in amanner that correlates closely
FIGURE 5. Relationship between TLS and FA core complex components.
A, exponentially growing HCT116 RAD18/ and RAD18/ cells were treated
with 100 nM BPDE for 2 h. Soluble (sol) and chromatin (chr) extracts from the
resulting cells were analyzed by SDS-PAGE and immunoblotting with
antibodies against FANCA, FANCD2, FANCG, RAD18, and phospho-Chk1 (Ser-
317). B, control (siCon) and Rad18-depleted (siRad18) cells were infected
with adenovirus encoding FLAG-Rad18 or HA-PCNA-Ub* fusion protein for
48 h. Soluble and chromatin extracts from the resulting cells were analyzed by
SDS-PAGE and immunoblotting with antibodies against FANCA, Rad18 and
PCNA. C, HCT116 cells were transfected with siPol oligonucleotides or con-
trol nontargeting siRNA (siCon). The resulting cells were treated with UVC (10
J/m2). Cell extracts were prepared 2 h after UV treatment and analyzed by
SDS-PAGE and immunoblotting using antibodies against FANCD2, FANCA,
pol , and phospho-Chk1 (Ser-317). D, GM6914 FANCA () fibroblasts or an
isogenic FANCA () cell line stably reconstituted with wild type FANCA was
infected with adenoviruses encoding Rad18 or PCNA-Ub* fusion protein or
treated with 300 nM MMC. Soluble and chromatin extracts from the resulting
cells were analyzed by SDS-PAGE and immunoblotting with antibodies
against the indicated proteins. E, control and UBE2T-depleted H1299 cells
were treated with 300 nM BPDE or 300 nM MMC for 6 h, or infected with
AdRad18 for 48 h. Soluble and chromatin extracts from the resulting cells
were analyzed by SDS-PAGE and immunoblotting with antibodies against
FANCD2, UBE2T, phospho-Chk1, cyclin A, and PCNA.
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with PCNA mono-ubiquitination. We have been unable to
demonstrate that FANCD2 is a direct substrate for ubiquityla-
tion by Rad18. However, we note that in vitro mono-ubiquiti-
nation of FANCD2 has been demonstrated successfully by only
two groups, and it had been a very challenging task to reproduce
complete mono-ubiquitination of FANCD2 in vitro (39, 40).
Therefore, our inability to detect Rad18-dependent FANCD2
ubiquitylation in vitro does not necessarily exclude the possi-
bility of a direct E3 ligase-substrate relationship between Rad18
and FANCD2. However, our results demonstrating a dependence
of FANCD2 ubiquitylation on PCNA mono-ubiquitination and
pol  strongly suggest that the mechanism by which Rad18 acti-
vatestheFApathwayisindirect.OurresultsindicatethattheRad18-
dependent mechanism of FA pathway activation requires the FA
core complex. Moreover, the FA core complex component
FANCA associates with chromatin in a manner that depends on
Rad18 and TLS polymerase recruitment (Fig. 7).
In RAD18-deficient cells, activation of the FA pathway is
attenuated but not entirely ablated,
indicating that compensatory or
partially redundant mechanisms
exist for FA pathway activation in
the absence of Rad18. Dutta and co-
workers (41) recently showed that
the CRL4Cdt2 complex supports a
basal level of PCNA ubiquitylation
and TLS, even in Rad18-deficient
cells. Therefore, CRL4Cdt1-depen-
dent TLS likely provides an addi-
tional mechanism for Rad18-inde-
pendent activation of the FA
pathway.
The FA pathway is generally
activated during S-phase and in
response to many replication fork-
stalling lesions, yet FANC de-
ficiency confers relatively specific
ICL hypersensitivity, an observation
attributed to redundant roles for FA
pathway in repair of other lesions.
Nevertheless, mild UV sensitivity of
FA cells has been reported (30). Our
results showing BPDE sensitivity of
FANCD2() cells are also consis-
tent with a role for the FA pathway
in processing and repair of bulky
adducts at stalled replication forks.
Relatively little is known regarding
the mechanisms dictating the
modes of lesion bypass for replica-
tion forks that encounter damaged
DNA. Nevertheless, it appears that
both TLS- and homologous re-
combination-based mechanisms
are available to cells bypassing bulky
adducts, including BPDE (42).
Therefore, coordinate activation of
both TLS and FA pathways may be
FIGURE 6. Effect of FANCD deficiency on PCNA mono-ubiquitylation. H1299
cells were transfected with siRNA against FANCD2, FANCI, or nontargeting con-
trol siRNA. The resulting cells were treated with 300 nM BPDE, 300 nM MMC, or
were left untreated for controls. Soluble and chromatin extracts from the result-
ing cells were analyzed by SDS-PAGE and immunoblotting with antibodies
against FANCD2, phospho-Chk1 (Ser-317), and PCNA as indicated.
FIGURE 7. Hypothetical model for Rad18-dependent activation of the FA pathway in response to
bulky DNA adducts. Bulky DNA adducts cause uncoupling of replicative helicase (Mcm2–7) and DNA
polymerase activities (step 1). The ensuing accumulation of replication protein A-coated ssDNA recruits
the Rad18-pol  complex leading to PCNA mono-ubiquitylation (step 2). Potentially, mono-ubiquitinated
PCNA might promote FA pathway activation via pol -independent mechanisms (step 3, pathway
depicted on left-hand side). Alternatively, engagement of pol  or other DNA TLS polymerases with mono-
ubiquitinated PCNA might generate protein complexes and/or DNA structures that facilitate the recruit-
ment of FA core complex members to sites of replication stalling, promoting FANCD2-FANCI ubiquitina-
tion (step 3, pathway depicted on right-hand side).
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advantageous for tolerance of replication forks stalled by bulky
DNA lesions.
Precisely how Rad18-dependent FA pathway activation is
coupled with TLSmay depend on the nature of the DNA lesion
encountered by replication forks. In the case of bulky DNA
adducts such as BPDE and cyclobutane pyrimidine dimers,
recent models suggest that uncoupling of helicase and poly-
merase activities generates replication protein A-coated
ssDNA that recruits Rad18 to sites of replication stalling (26,
43). Soluble Rad18 exists in a complex with pol and is thought
to chaperone pol  (and perhaps other TLS polymerases) to
sites of replication fork stalling (8). Once recruited to stalled
replication forks, Rad18 performs PCNAmono-ubiquitination
(4). Depending on the identity of the DNA adduct, one or more
TLS polymerases are thought to perform the insertion and
extension steps of TLS.
Our results indicate that PCNA ubiquitination facilitates
efficient activation of the FA pathway. The stimulatory effect of
mono-ubiquitinated PCNA on the FA pathway activation may
be mediated via pol  or other TLS DNA polymerases (Fig. 7,
pathway depicted on right-hand side of step 3), a possibility that
is supported by our pol  depletion experiments. According to
this model, the TLS intermediate of mono-ubiquitinated
PCNA in complex with pol  and possibly ssDNA or other
DNA structures might be coupled to the activation of the FA
core complex, leading tomono-ubiquitination of FANCD2 and
FANCI. It is possible that the complex of mono-ubiquitylated
PCNA with pol  (or other TLS polymerases) or replication
structures generated duringTLS provide a platform for FApro-
teins. Consistent with this possibility, Glover and co-workers
(44) have identified a functional PCNA-interacting peptide-
box in FANCD2.
Alternatively, putative effectors of PCNA-Ub other than pol
 might contribute to efficient FA pathway activation (Fig. 7,
pathway depicted on left-hand side of step 3). According to this
scheme, the role of pol  is solely to promote efficient PCNA
ubiquitination via mutually dependent formation of active
Rad18-pol  complexes.
These results invite further questions regarding the role(s) of
FA proteins in the tolerance and processing of bulky DNA
adducts. Studies using yeast andDT40 cells indicate that PCNA
ubiquitination and pol  are not required for ongoing replicon
movement in UV-irradiated cells but instead play an important
role in preventing accumulation of ssDNA gaps behind the rep-
lication fork (45, 46). Details of the putative re-priming mech-
anism thatmaintains leading strand synthesis on damaged tem-
plates are not well understood (47). Nevertheless, if the basic
mechanisms of TLS are conserved in yeast, chicken (DT40),
and mammalian cells and if TLS does indeed occur post-repli-
catively, it appears likely that Rad18-dependent activation of
FA pathway is initiated behind re-primed replication forks.
It is possible that the FA pathway plays a role in the putative
re-priming mechanism. Reportedly, the FA core complex is
necessary for Rev1 recruitment (21, 27), and inDT40 cells, Rev1
is required for efficient replicon elongation in the presence of
DNA damage (46). Therefore, because of its role in Rev1
recruitment, the FA core complex might be necessary for
maintaining replicon elongation independently of FANCD2
ubiquitination.
Activation mechanisms of the TLS and FA pathways might
be very different when replication forks encounter ICL and
might differ between species and cell type. Elegant studies using
replication-competent Xenopus cell-free extracts have demon-
strated a requirement of the FANCD2-FANCI complex for
lesion bypass by replication forks that converge on an ICL.
Those studies demonstrated that essential factors for lesion
bypass (including the TLSDNApolymerase pol ) are recruited
in a manner that requires mono-ubiquitinated FANCD2-
FANCI during replication-coupled ICL repair (17, 37). The
roles of Rad18 and mono-ubiquitylated PCNA during replica-
tion-coupled ICL repair have not yet been reported in that
experimental system. However, if Rad18 and PCNA ubiquity-
lations are required for FANCD2-mediated bypass when repli-
cation forks converge on ICL, it appears most likely that Rad18
functions downstream of the FA core complex.
Although replication forks converging simultaneously on
cross-links in the context of a small plasmid template (17)
require FANCD2-FANCI for replication-coupled bypass, it is
possible that not all ICLs are processed via this mechanism in
mammalian cells harboring genome-wide DNA damage. For
instance, it is not clear whether the processing of ICL encoun-
tered by a replication fork in the context of a larger template (i.e.
the mammalian genome) is delayed until arrival of a second
converging fork. Thus, the elegant experimental system
employed byWalter and co-workers (37) (which involves a sin-
gle defined cross-link engineered into a small plasmid) is very
different from cultured mammalian cells containing bulky
adducts and direct comparison with results of our experiments
may be inappropriate.
The study by Walter and co-workers is arguably the best
defined example of cooperative actions of TLS and FAproteins,
and it is clear from those studies that FANCD2 functions
upstream of pol . Our results indicate that there is not invari-
ably a simple linear relationship between the TLS and FA path-
ways. However, this does not imply any disagreement between
the two studies. We note also that different DNA repair pro-
teins frequently have complex interactions in which clear prox-
imal/distal relationships do not exist. For example, the p95/
NBS1 protein is both an upstream component of the ataxia
telangiectasia mutated signaling pathway and a target of ataxia
telangiectasia mutated signaling.
In summary, our data provide a novel mechanism for cross-
talk between the TLS and FA pathways. Taken together with
previous results, it appears that signaling between FA and TLS
mechanisms can be bi-directional and that multiple compo-
nents of the FA and TLS pathways may communicate. More-
over, the nature of the DNA damage (bulky adducts, ICL) and
perhaps other factors influence the mechanism and direction-
ality of the cross-talk.
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